

IN THE CLAIMS:

Prior to calculation of the fee, please cancel claims 1-19 and add new claims 20-23 as

follows:

20. A method of detecting thyroid-associated ophthalmopathy in a patient comprising:

obtaining a biological sample from the patient, [and ]

isolating IgG from the patient sample,

exposing the IgG to orbital fibroblasts from patients with thyroid-associated ophthalmopathy,

measuring the level of

IL-16 or

RANTES produced by the orbital fibroblasts,

wherein an elevated level of IL-16 or RANTES indicates the presence or severity of thyroid-associated ophthalmopathy in the patient.

21. The method of claim 20 wherein the level of IL-16 or RANTES is measured by an Enzyme-Linked Immunosorbent Assay (ELISA).

22. The method of claim 20 wherein the patient is human.

10046651-101901

23. The method of claim 20 wherein the biological sample is selected from the group  
consisting of:

blood,

urine,

synovial fluid,

ascites,

tissue.

A3

1004651.101901


The present application is filed to correct inventorship to add Dr. William Cruikshank as provided by MPEP Section 201.03. The amendment to the claims and specification addresses items raised by the Examiner in the action in the parent application. An additional response to address prior art issues raised in the Action will be submitted in this continuing application.

Respectfully submitted,

LYON & LYON LLP

Dated: October 19, 2001

By:

  
Kurt T. Mulville  
Reg. No. 37,194  
Attorneys for Applicants

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
949/567-2300 X 1124  
213/955-0440 Facsimile